| Cat # | Size | Price | Quantity | |
|---|---|---|---|---|
| 814401 | 25 ug | $145 | ||
| 814402 | 100 ug | $295 |
| Application | ELISA, BLI |
|---|---|
| Format | Liquid, Purified |
| Expression Host | CHO |
| Target Name | EphA2 |
| Species | Human |
| Sources | Recombinant Human EphA2 (Gln25-Asn534) with C-terminus His-tag is expressed in CHO cell. |
| Accession Number | P29317 |
| Molecular Weight | The protein has a predicted molecular weight of 57.7 kDa. Under DTT-reducing conditions, it migrates at approximately 60 kDa on SDS-PAGE. |
| Affinity Tag | C-His |
| Purity | >95% based on SDS-PAGE under reducing condition |
| Regulatory Status | RUO |
| Formulation | 1xPBS buffer, pH7.4, 0.22 µm filtered |
| Endotoxin level | Not tested |
| Protein Concentration | 25µg size is bottled at 0.2mg/mL concentration. 100 µg size is supplied at a lot-specific concentration. |
| Storage and Handling | Briefly centrifuge the vial upon receipt. An unopened vial can be stored at 4°C for up to 2 weeks, or at -20°C or below for up to six months. The protein may be further diluted to 0.1 mg/mL using 0.22 µm-filtered PBS buffer (pH 7.4). For long-term storage, the diluted stock solution should be aliquoted and stored at ≤ –70°C to minimize freeze-thaw cycles. If additional dilution is required, carrier proteins such as FBS or BSA should be added to maintain protein stability. |
EphA2 (Ephrin type-A receptor 2) is a receptor tyrosine kinase involved in cell adhesion, migration, and tissue organization. It plays a critical role in embryonic development and angiogenesis. EphA2 is frequently overexpressed in various cancers, including breast, lung, and prostate cancer. Overexpression is associated with increased tumor growth, invasiveness, and poor clinical outcomes. Because of its role in promoting tumor progression, EphA2 is being actively explored as a therapeutic target in oncology. Therapeutic strategies include monoclonal antibodies, small molecule inhibitors, and antibody-drug conjugates targeting EphA2-positive tumors.
